News Ipsen's Cabometyx recommended by NICE for previously treated... French drugmaker Ipsen’s Cabometyx (cabozantinib) has been recommended by the National Institute for Health and Care
Oncology Servier’s ASCO 2025 Data: Advancing IDH-Mutated Cancer Treat... At ASCO 2025, Servier’s Becky Martin discusses IDH-mutated cancers, including key insights on Tibsovo & Voranigo, and the implications for patients.
